1
 
 
Home News & Events COMPETITION LAW NEWS: EU Commission Ceases Investigation into Pharmaceutical Suspected Practices

COMPETITION LAW NEWS: EU Commission Ceases Investigation into Pharmaceutical Suspected Practices

Sunday, 11 March 2012 23:36

Following the dawn raids carried out in November 30, 2010 by the EU Commission in several Member States on the premises of AstraZeneca and Nycomed, two leading pharmaceutical companies, on March 1st, 2012, the European Commission announced that it has ceased its investigations on the operations of two companies which investigations focused on a “suspected individual or joint action to delay the market entry of generic medicines” by the relative pharmaceutical companies.

Indeed, in 2008 and 2009, the EU Commission had carried out an extensive investigation into the pharmaceutical sector with a primary focus on suspected practices by certain pharmaceutical companies with the aim to delay the market entry of generic medicines, to the detriment of millions of consumers on the European scenario.

This led to regular monitoring of potentially problematic patent settlements.

Leading pharamceutical companies like Servier, Cephalon and Johnson & Johnson have all been investigated for possible breach of EU competition regulations specifically Article 101 and Article 102 of the Treaty on the Functioning of the EU (TFEU).

 

Further Reading:

http://europa.eu/rapid/pressReleasesAction.do?reference=IP/12/210&format=HTML&aged=0&language=EN&guiLanguage=en